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Background. Achieving effective antiretroviral treatment (ART) monitoring is a key determinant to ensure viral suppression 
and reach the UNAIDS 90-90-90 targets. The gold standard for detecting virological failure is plasma human immunodeficiency 
virus (HIV) RNA (viral load [VL]) testing; however, its availability is very limited in low-income countries due to cost and opera-
tional constraints.
Methods. HIV-1–infected adults on first-line ART attending routine visits at the Manhiça District Hospital, Mozambique, were 
previously evaluated for virologic failure. Plasma levels of interferon-γ–inducible protein 10 (IP-10) were quantified by enzyme-
linked immunosorbent assay. Logistic regression was used to build an IP-10–based model able to identify individuals with VL >150 
copies/mL. From the 316 individuals analyzed, 253 (80%) were used for model training and 63 (20%) for validation. Receiver oper-
ating characteristic curves were employed to evaluate model prediction.
Results. From the individuals included in the training set, 34% had detectable VL. Mean age was 41 years, 70% were females, 
and median time on ART was 3.4  years. IP-10 levels were significantly higher in subjects with detectable VL (108.2 pg/mL) as 
compared to those with undetectable VL (38.0 pg/mL) (P < .0001, U test). IP-10 univariate model demonstrated high classification 
performance (area under the curve = 0.85 [95% confidence interval {CI}, .80–.90]). Using a cutoff value of IP-10 ≥44.2 pg/mL, the 
model identified detectable VL with 91.9% sensitivity (95% CI, 83.9%–96.7%) and 59.9% specificity (95% CI, 52.0%–67.4%), values 
confirmed in the validation set.
Conclusions. IP-10 is an accurate biomarker to screen individuals on ART for detectable viremia. Further studies should evalu-
ate the benefits of IP-10 as a triage approach to monitor ART in resource-limited settings.
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In 2014, the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) announced bold new targets for the global response 
to human immunodeficiency virus (HIV), commonly known 
as the 90-90-90 strategy, consisting of 90% of people living with 
HIV aware of their status, 90% of people diagnosed with HIV on 
treatment, and 90% of people on treatment attaining virologic 
suppression, by 2020 [1]. Although considerable international 
efforts have resulted in a dramatic increase in antiretroviral 
therapy (ART) coverage in the last years, relatively little pro-
gress has been achieved in the development of simple, accur-
ate, and affordable tools that allow proper surveillance of ART 
efficacy [2, 3]. In 2013, the World Health Organization (WHO) 
recommended routine HIV RNA (viral load [VL]) testing at 
6 months after ART initiation and every 12 months as the pre-
ferred monitoring approach to supervise treatment adherence 
and minimize failure [4]. According to the last WHO guidelines, 
virologic failure (VF) is defined by a persistently detectable VL 
>1000 copies/mL after at least 6 months of starting a new ART 
regimen [5]. VL monitoring is important for timely diagnosis 
of VF to allow early adherence interventions, prevent further 
transmissions, and avoid delays in regimen switches that could 
lead to disease progression or emergence of drug resistances 
[6]. However, despite the international recommendations, VL 
testing is still not widely available in many low- and middle-in-
come countries (LMICs) due to high cost and implementation 
constraints [3, 7]. The alternative to VL has often been clinical 
and/or immunological monitoring, which frequently results in 
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patients remaining on failing ART as well as unnecessary regi-
men switches [8, 9].
Expression of several inflammatory and immune response 
cytokines is increased during HIV replication [10]. Previous 
studies have shown that plasma levels of interferon-γ–inducible 
protein 10 (IP-10) correlated with VL [11, 12] and VL set-point 
[13] during untreated primary HIV infection and decline after 
ART initiation both in early [14] and chronically HIV-infected 
individuals [15]. Similarly, we have seen that from a total of 42 
inflammatory biomarkers, IP-10 shows the strongest associ-
ation with VL and the best predictive power to identify acute 
HIV infection among febrile seronegative patients (Pastor et al, 
manuscript in preparation). We hypothesized that, because of 
its strong association with VL, plasma IP-10 level could be a 
surrogate marker of detectable viremia in ART-treated individ-
uals, providing a simple and affordable screening tool to detect 
individuals with VF in LMICs.
METHODS
Study Population
The present analysis is a substudy of a cross-sectional cohort 
for detecting drug resistance in ART-treated adults enrolled 
between February and March 2013 at the Manhiça District 
Hospital (MDH), Maputo, southern Mozambique [16]. At 
the time of the study, current HIV national guidelines recom-
mended ART initiation in patients with a CD4 T-cell count ≤350 
cells/μL, and no routine VL monitoring was provided after ART 
initiation. The study protocol was approved by the institutional 
review boards and ethics committees of the Barcelona Clinic 
Hospital, Badalona Germans Trias i Pujol Hospital, Spain, and 
the National Committee on Health Bioethics, Mozambique. All 
study participants provided signed informed consent.
In brief, adults >18 years of age attending routine scheduled 
outpatient visits for clinical management of HIV/AIDS at the 
MDH were enrolled in the study. All patients had documented 
HIV infection, documented ART initiation ≥12 months earlier, 
and provided written informed consent. The sample and data 
collection procedures have been previously described [16] and 
include a single blood sample and sociodemographic and clin-
ical data collected in a specific questionnaire.
Laboratory Procedures
HIV RNA levels were determined in plasma samples by 
reverse-transcription polymerase chain reaction (Abbott m2000 
RealTime System with a detection limit of 150 copies/mL), and 
CD4+ T-cell counts were determined in whole blood by flow 
cytometry using FACSCalibur (BD Biosciences) as previously 
described [16]. IP-10 level was measured in plasma samples by 
enzyme-linked immunosorbent assay (Human Duo-Set ELISA, 
R&D Systems, Minneapolis, Minnesota) according to the man-
ufacturer’s instructions; 0.05% Tween-20 (Sigma-Aldrich, St 
Louis, Missouri) 1% bovine serum albumin (Sigma-Aldrich) in 
phosphate-buffered saline was used as blocking solution, 3, 3′, 
5, 5′-tetramethylbenzidine (Sigma-Aldrich) as substrate, and 4N 
sulfuric acid as stop solution. Optical density was measured at 
492 and 620 nm. Values assigned to data falling outside quantifi-
cation limits were the double and the half of the upper and lower 
quantification limits, respectively.
Statistical Analysis
Data were double-entered using Fox Pro version 2.6 (Microsoft 
Corporation, Redmond, Washington) and analyzed using 
R-3.2.2 software and Stata version 14 software (StataCorp, 
College Station, Texas).
Proportions and continuous variables were compared using 
χ2 and nonparametric Mann-Whitney U test, respectively. IP-10 
values were log transformed for a better adjustment of skewed 
data. Spearman test was used to assess correlation coefficients 
for continuous variables.
To assess the capacity of IP-10 levels and clinical variables to 
correctly identify the cases, logistic regression with penalized like-
lihood was performed [17]. According to random selection of the 
316 individuals included in this analysis, 80% were used for data 
analysis and model construction (n = 253) and 20% for model val-
idation (n = 63). A multivariate logistic regression model was built 
applying a stepwise selection to the set of variables: IP-10, sex, age, 
CD4 T-cell count, body mass index (BMI), days on ART, and pres-
ence of symptoms. In the selection, variables with P values <.05 
could enter into the model whereas a P value <.10 was required to 
be retained. Outcomes tested were detectable VL (defined as HIV 
RNA >150 copies/mL) and VF (defined as HIV RNA >1000 cop-
ies/mL). Diagnostic capacity was determined using receiver oper-
ating characteristic (ROC) analyses. ROC curves from univariate 
and multivariate models were compared for the best prediction.
RESULTS
Population Characteristics
Of the 332 individuals included in the cross-sectional analysis 
for drug resistance [16], IP-10 was determined in 316 (95.2%). 
We thus trained our model on 253 (80%) of the individuals 
with available IP-10 data. The mean age of the 253 individu-
als included in the training set was 41  years (standard devi-
ation [SD], 10 years) and 70% were females. Median time on 
ART was 3.4  years (interquartile range [IQR], 2.1–5.3  years) 
and 89% were receiving zidovudine/lamivudine/nevirapine at 
the time of the survey. Mean BMI was 23.2 kg/m2 (SD, 3.9 kg/
m2), median CD4 T-cell count was 439 cells/μL (IQR, 273–593 
cells/μL), and 38% presented any type of symptoms at the time 
of the survey. Thirty-four percent had detectable VL (86/253) 
and 25% (64/253) met criteria for the standard definition of VF 
(VL >1000 copies/mL) [4]. In contrast, when clinical and immu-
nological criteria were used, only 12% (29/245) of subjects were 
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suspected to have ART failure. Population characteristics did 
not significantly differ from those of individuals included in the 
cross-sectional analysis of resistance [16] nor of those included 
in the validation set (P > .1).
Evaluation of an Interferon-γ–Inducible Protein 10–Based Model to 
Identify Detectable Viremia
Median IP-10 levels were significantly higher among individ-
uals with detectable VL compared to those with undetectable 
VL (108.2 pg/mL vs 38.0 pg/mL, respectively; U test P < .0001; 
Figure 1). IP-10 levels did not significantly differ from those of 
individuals included in the validation set (P > .1). Among those 
individuals with detectable VL, IP-10 levels were significantly 
correlated with VL (ρ = 0.33, P = .002).
Univariate analysis showed that IP-10 was significantly and 
positively associated with detectable VL (odds ratio,  1.47 per 
10% IP-10 pg/mL increase; P < .0001). The ROC curve demon-
strated high predictive power for classification of individuals 
with detectable VL with an area under the curve (AUC) = 0.85 
(95% confidence interval [CI], .80–.90). Sex, age, BMI, CD4 
T-cell count, days on ART, and presence of any symptoms at the 
visit day were considered for inclusion in a multivariate analysis 
together with IP-10. However, only IP-10 and CD4 T-cell count 
were retained in the model and the resulting multivariate model 
did not increase the classification performance (AUC  =  0.85 
[95% CI, .80–.90]; Figure 2).
Then, ROC curve for the univariate IP-10 model was used to 
evaluate several cutoff values prioritizing the highest sensitivity. 
A cutoff of IP-10 ≥44.2 pg/mL was selected, providing a sen-
sitivity of 91.9% (95% CI, 83.9%–96.7%) and a specificity of 
59.9% (95% CI, 52.0%–67.4%) for predicting detectable viremia 
(Figure 2B).
The IP-10 model with a cutoff of ≥44.2 pg/mL was assessed 
for predictive accuracy to identify individuals with detectable 
VL. We calculated positive and negative predictive values (PPV 
and NPV, respectively) using model sensitivity and specificity 
and their respective 95% CIs (Figure  3). Applying the preva-
lence of detectable VL of 36% observed in the cross-sectional 
resistance study [16] and the IP-10 model sensitivity and speci-
ficity, the PPV would be 56.3% (Figure 3A) and the NPV would 
be 92.9% (Figure 3B).
Validation of the Model Accuracy
When we applied the IP-10 model to the validation panel of 
samples, 80% of the 20 individuals with detectable VL and 58% 
of the 43 individuals with undetectable VL were correctly classi-
fied. The sensitivity and specificity derived from the validation 
panel were not statistically different from those obtained with 
the training set (equality of proportions test P = .115 and .953, 
respectively), thus confirming the predictive power of the uni-
variate IP-10 model for identification of ART-treated individu-
als with detectable VL.
The prevalence of standard VF (VL  >1000 copies/mL) 
observed in the study population was 25% (64/253). Both uni-
variate and multivariate models were also tested for their ability 
to detect individuals with standard VF, showing lower specific-
ity for a given sensitivity than the model designed to identify 
individuals with detectable VL (VL >150 copies/mL; data not 
shown).
Comparison of Plasma Interferon-γ–Inducible Protein 10 Versus Human 
Immunodeficiency Virus-RNA Quantification to Predict Detectable 
Viral Load
We then combined the training and validation panels to esti-
mate the number of VL assays required for ART monitoring 
in this population using either the IP-10–based algorithm or 
standard VL testing (Table  1). Whereas using VL monitoring 
alone would require 316 VL determinations to detect 106 indi-
viduals harboring detectable VL, the use of an IP-10 screening 
test followed by VL confirmation would only require 180 VL 
determinations. The IP-10 screening test would thus require 
43% fewer VL determinations and identify 89.6% of those with 
detectable VL in this sample population.
An analysis from the Global Fund’s Price and Quality 
Reporting Tool found that VL reagent costs alone varied from 
US $13.13 to US $43.34 between countries [3, 18]. Considering 
US$28 as the average reagent cost for HIV-VL testing, trans-
lated to dollar values, the VL testing of these 316 treated indi-
viduals would imply around US$8850 per year to the health 
system. On the other hand, considering a unit cost of US$1.50 
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Figure  1. Comparison of interferon-γ–inducible protein 10 (IP-10) levels in 
antiretroviral therapy–treated individuals with and without detectable viral load 
(VL >150 copies/mL). Box as interquartile range (IQR), middle line as median, whisk-
ers as Tukey values (1.5 × IQR) and dots as outliers. Nonparametric U test signifi-
cance is indicated  as “****” for P < .0001.
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based on costs for other similar cytokines [19], the IP-10 
screening, together with the 180 VL determinations required 
in this cohort, would imply a cost of around US$5510 per year. 
This means that introducing an IP-10–based screening for ART 
monitoring would save US$3340 a year for this cross-sectional 
study cohort, resulting in savings of 38% in VL-associated cost.
DISCUSSION
We have demonstrated that a cutoff value for IP-10 of ≥44.2 
pg/mL gave a sensitivity of 91.9% (95% CI, 83.9%–96.7%) and 
a specificity of 59.9% (95% CI, 52.0%–67.4%) for predicting 
detectable viremia in individuals on ART for more than a year. 
Thus, we have shown that IP-10 is a simple biomarker that 
can be used to screen individuals on ART for VF, reducing the 
number of costly VL determinations required to monitor ART 
in LMICs.
The most recent WHO guidelines recommend routine track-
ing of ART effectiveness using VL testing at 6 and 12 months 
after treatment initiation and every 12 months in stable patients 
to minimize treatment failure [5]. However, the high cost and 
technical complexity of VL testing has hampered scale-up in 
resource-limited settings. In absence of routine VL testing, 
the use of clinical and CD4 monitoring in many sub-Saharan 
African countries has been shown to favor the emergence of 
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Figure 3. Accuracy of the interferon-γ–inducible protein 10 model for identifying patients with detectable viral load according to the observed prevalence of individuals on 
antiretroviral therapy with detectable viremia. A, Positive predictive value (PPV) estimated for sensitivity (Se) = 91.9% and 3 different specificity (Sp) scenarios according to 
the estimated confidence interval (Sp = 59.9% [95% confidence interval, 52.0%–67.4%]). B, Negative predictive value (NPV) estimated for specificity = 59.9% and 3 different 
sensitivity scenarios according to the estimated confidence interval (Se = 91.9% [95% CI, 83.9%–96.7%]). Dashed/dotted line indicates PPV and NPV at the prevalence of 
detectable VL observed in the cross-sectional resistance study [16].
Figure 2. Performance of univariate and multivariate interferon-γ–inducible protein 10 (IP-10) models in predicting detectable viral load. A, Comparison between receiver 
operating characteristic (ROC) curves for univariate IP-10 model (line with circles) and multivariate model (line with triangles) including IP-10 and CD4 T-cell count. IP-10 
univariate model cutoff points (pg/mL) (B) and multivariate model score cutoff points (C) with their respective sensitivity and specificity values.
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VF and drug resistances [8, 16]. In Mozambique, recent cross-
sectional surveys reported that 23% [7] and 36% [16] of individ-
uals on ART, in Maputo and Manhiça District, respectively, had 
detectable HIV viremia.
IP-10 is an inflammatory cytokine produced as part of the 
innate immune response to different pathogens [20]. IP-10 has 
been explored for its use as both a diagnostic and prognostic 
marker for several infectious diseases, such as malaria, hepa-
titis C, or tuberculosis [20–22]. In the case of HIV infection, 
previous data suggested that IP-10 levels were predictive of dis-
ease progression [11, 23] and significantly decreased between 
6 months [14] and 2 years [15] after ART initiation; however, to 
our knowledge, the use of IP-10 as a biomarker for VL levels has 
not been assessed for its accuracy to detect VF in individuals 
on ART.
Our results show that IP-10 can indeed be used as a surro-
gate marker of VL with high accuracy to screen ART-treated 
individuals and identify patients most likely to have VL levels 
>150 copies/mL. This is particularly relevant in countries with 
scarce resources where the scale-up of ART often leads to delays 
and even failure to return VL results due to congested and/or 
centralized health facilities, which compromises both quality 
health services and patient retention in care [3]. Health and lab-
oratory system strengthening together with reductions in costs 
and decentralization of services are required to implement the 
effective VL monitoring necessary to reach UNAIDS 90-90-90 
targets in low-income settings [3]. Here we suggest a new algo-
rithm to reduce the cost of ART monitoring by using IP-10 as 
a screening tool to target the individuals on ART most likely to 
require VL testing. Thus, allocation of resources to VL would 
be prioritized without jeopardizing quality of care. In a limit-
ed-resource setting, an IP-10 assay would halve the number of 
VL tests required to monitor the same number of patients and 
could be combined with pooled VL testing to further reduce 
the number of VL assays [7].. Despite the difficulty of adding 
an extra test to a clinical algorithm, IP-10 can be quantified 
by an inexpensive commercially available enzyme immuno-
assay with a 4-hour turnaround time and could be developed 
into a point-of-care test, as have other similar cytokines [19]. 
Therefore, WHO recommendations would be followed but 
VL testing would be requested only if IP-10 screening indi-
cates potential VF. Standard recommendations for counseling, 
adherence support, and repeating VL within a 3-month interval 
would continue to be fulfilled to determine VF and subsequent 
antiretroviral regimen switching following WHO guidelines 
[5]. Pilot studies could be designed to evaluate the feasibility of 
integrating this test into existing laboratory facilities.
IP-10 is an affordable and easily quantifiable biomarker; 
however, its expression level is affected by a number of inflam-
matory responses [20]. Hence, its potential use to identify VF 
would require a second step of confirmation through VL. In this 
subanalysis of the cross-sectional study carried out in adults on 
ART at the MDH in southern Mozambique [16], to detect the 
34% of individuals with detectable VL, 316 VL tests were neces-
sary. However, using IP-10 to screen out those individuals not 
likely to have VF, only 180 VL tests would have had to be con-
ducted, thus reducing by 43% the VL determinations required 
for ART monitoring in these settings. Although there are major 
pricing discrepancies across countries and policies globally 
[3], and disregarding costs of instrument maintenance, human 
resources, sample transportation, and indirect cost associated 
to late VF detection, according to data from our cohort, this 
approach could potentially save 38% of VL-derived costs to the 
health system. Nevertheless, this IP-10–based screening is not 
only presented as a cost-saving strategy, but also, and maybe 
more importantly, as a way to decongest the overloaded core 
health and laboratory facilities. Even though most of the cases 
with detectable viremia were identified by employing IP-10 test-
ing, up to 10.4% were misclassified as not requiring VL con-
firmation. This represents an important population whose VF 
would remain undiagnosed. However, depending on the setting 
in LMICs, the consequences of this misclassification need to be 
weighed against the risks of a higher proportion of individuals 
not receiving VL monitoring due to overburdened or isolated 
health services.
As IP-10 plasma level is influenced by immune recovery [24], 
we assessed a multivariate model including clinical variables; 
however, predictive power was not significantly increased. 
Further studies should evaluate whether a combination of 
IP-10 with another inflammatory cytokine involved in viro-
logical responses or any other surrogate of immune activation 
could improve the accuracy for predicting detectable viremia 
and reduce misclassification. Moreover, optimization of model 
parameters across HIV subtypes and comorbidities present in 
different populations as well as sample types including dried 
blood spots (DBSs) could render this approach generalizable. 
Indeed, recent studies have shown accurate VL measurements 
by using DBS to monitor patients on ART in low-income set-
tings [25]. IP-10 levels have also been demonstrated to be eas-
ily and precisely quantifiable in DBSs [26], and this approach 
has been recently validated for the diagnosis of tuberculosis 
Table 1. Interferon-γ–Inducible Protein 10 Classification Performance for 
Predicting Viremia Compared to Gold Standard Viral Load
VL Result (Gold Standard)
IP-10 Classification Undetectable VL Detectable VL Total
No case 125 (59.5) 11 (10.4) 136 (43.0)
Potential VF 85 (40.5) 95 (89.6) 180 (57.0)
Total 210 (100) 106 (100) 316 (100)
Data are presented as No. (%). IP-10 model with a cutoff of ≥44.2 pg/mL was compared to 
gold standard VL for classification performance of individuals with detectable VL (>150 cop-
ies/mL). Note that both training and validation sets were included to simulate a hypothetical 
classification in a cross-sectional cohort in Mozambique.
Abbreviations: IP-10, interferon-γ–inducible protein 10; VF, virologic failure; VL, viral load.
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[27] and monitoring antituberculosis treatment response [28]. 
Further studies should evaluate the predictive power of IP-10 
levels quantified in DBSs to identified cases with detectable 
viremia among ART-treated individuals. This strategy would 
offer decentralized VF diagnosis, facilitate sample storage and 
transportation, and reduce test unit cost [29].
We thus propose a novel IP-10 screening algorithm for detec-
tion of VF. At a time when UNAIDS estimated that 18.2 million 
people were receiving ART in 2016 and nearly 12.7 million peo-
ple will initiate ART in the next few years [30], further studies 
are warranted to assess the impact of implementing this sim-
ple triage approach to reduce the volume of VL determinations 
required for monitoring viral suppression.
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